

ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom
7-9 March 2018

CO-CHAIRS:

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom

SPEAKERS:

Mo Al Aloul, United Kingdom
Neil Bayman, United Kingdom
Haval Balata, United Kingdom
Benjamin Besse, France
Richard Booton, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Martin Früh, Switzerland
Marina Garassino, Italy
Pilar Garrido, Spain
Gerry Hanna, United Kingdom
Keith Kerr, United Kingdom
Rohit Kochhar, United Kingdom

Jaroslaw Kuzdzal, Poland
Cecile Le Pechoux, France
Catherine McBain, United Kingdom
Silvia Novello, Italy
Ugo Pastorino, Italy
Giorgio Scagliotti, Italy
Suresh Senan, Netherlands
Hamid Sheikh, United Kingdom
Tora S. Solheim, Norway
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Paul E. Van Schil, Belgium
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with **15 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certain medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

Wednesday, 7 March 2018

08:15-09:15 60'	Registration	
09:15-10:55 100'	SESSION 1 Screening and diagnostics for lung cancer	Chairs: Raffaele Califano, UK and Keith Kerr, UK
40'	Lung cancer screening: Pro and Contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith Kerr, UK
10:55-11:15	Coffee break	
11:15-12:15 60'	SESSION 1 Screening and diagnostics for lung cancer - cont.	Chairs: Fiona Blackhall, UK and Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
12:15-13:05	Lunch	
13:05-14:05 60'	SESSION 2 Radical treatment of early stage NSCLC	Chairs: Cecile Le Pechoux, FR and Ugo Pastorino, IT
30'	Surgery for early stage NSCLC	Ugo Pastorino, IT
30'	Adjuvant radiotherapy for completely resected early stage NSCLC	Cecile Le Pechoux, FR
14:05-14:25	Coffee Break	
14:25-15:25 60'	SESSION 2 Radical treatment of early stage NSCLC – cont.	Chairs: Cecile Le Pechoux, FR and Ugo Pastorino, IT
30'	Adjuvant chemotherapy for resected early stage NSCLC	Paul Taylor, UK
30'	Treatment of ALK positive advanced NSCLC	Fiona Blackhall, UK
15:25-15:35 10'	Close of day 1	Chairmen

Thursday, 8 March 2018

09:05-11:05 120'	SESSION 3 Advanced NSCLC	Chairs: Silvia Novello, IT and Benjamin Besse, FR
30'	Stereotactic ablative RT for early stages NSCLC	Suresh Senan, NL
30'	1 st line chemotherapy for advanced NSCLC	Benjamin Besse, FR
30'	2 nd line treatment for advanced NSCLC	Silvia Novello, IT
30'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
11:05-11:25	Coffee break	
11:25-12:45 80'	SESSION 3 Advanced NSCLC - cont.	Chairs: Yvonne Summers, UK and Marina Garassino, IT
20'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK
30'	Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
30'	Immune checkpoint blockade for NSCLC	Marina Garassino, IT
12:45-13:35	Lunch	
13:35-15:05 90'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Chairs: Catherine McBain, UK and Giorgio Scagliotti, IT
30'	Systemic treatment of mesothelioma	Giorgio Scagliotti, IT
30'	Treatment of oligometastatic NSCLC	Jaroslawn Kuzdzal, PL

30'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Catherine McBain, UK
15:05-15:25	Coffee break	
15:25-16:25 60'	SESSION 4 Palliative treatment of lung cancer and mesothelioma - cont.	Chairs: Raffaele Califano, UK and Tora S. Solheim, NOR
30'	Supportive and palliative care in lung cancer	Tora S. Solheim, NOR
30'	Intra-luminal radiotherapy	Hamid Sheikh, UK
16:25-16:35 10'	Close of day 2	Chairmen
18:30	Welcome drink	
19:00	Dinner	

Friday, 9 March 2018

09:05-10:35 90'	SESSION 5 Locally advanced NSCLC	Chairs: Paul E. Van Schil, BE and Corinne Faivre-Finn, UK
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Gerry Hanna, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:35-11:00	Coffee break	
11:00-12:00 60'	SESSION 5 Locally advanced NSCLC - cont.	Chairs: P Van Schil, BE and Corinne Faivre-Finn, UK
3x20'	3 x Participant clinical case discussion	Faculty

Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion

12:00-12:50	Lunch	
12:50-14:20 90'	SESSION 6 SCLC	Chairs: Pilar Garrido, ES and Corinne Faivre-Finn, UK
30'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
30'	Treatment of extensive stage SCLC	Martin Früh, CH
30'	Targeted agents in SCLC	Pilar Garrido, ES
14:20-14:40	Coffee break	
14:40-15:40 60'	SESSION 6 SCLC - cont.	Chair: Corinne Faivre-Finn, UK and Raffaele Califano, UK
30'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
30'	Versatility of circulating tumour cells in SCLC – biomarkers, biology, mouse models and drug development	Fiona Blackhall, UK
15:40-15:50 10'	Conclusion and farewell	Raffaele Califano, UK